90 -2 (88) 2026 - Khodzhiev B.B., Boltaeva M.M. - CLINICAL MANIFESTATIONS OF THE COMORBID COURSE OF GALLSTONE DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE

CLINICAL MANIFESTATIONS OF THE COMORBID COURSE OF GALLSTONE DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE

Khodzhiev B.B. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Boltaeva M.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease that is not associated with alcohol consumption in hepatotoxic doses. It has various histological forms, ranging from simple steatosis to non-alcoholic steatohepatitis or fibrosis, and may potentially progress to end-stage liver disease, cirrhosis, or hepatocellular carcinoma [1]. The consequences of NAFLD are not limited to morbidity and mortality associated with disease progression, as the condition is closely related to extrahepatic risks, including cardiovascular diseases (CVD), chronic kidney disease, type 2 diabetes mellitus (T2DM), and osteoporosis. The biological mechanisms by which NAFLD leads to associated diseases have not yet been fully elucidated.

Keywords: Non-alcoholic fatty liver disease, fibrogenesis, insulin resistance index, lipid profile.

First page

461

Last page

466

For citation:Khodzhiev B.B., Boltaeva M.M. - CLINICAL MANIFESTATIONS OF THE COMORBID COURSE OF GALLSTONE DISEASE AND NON-ALCOHOLIC FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 461-466 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl.):S47-64. doi: 10.1016/j.jhep.2014.12.012
2. Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. doi: 10.1097/MD.0000000000010214
3. Abdeldyem SM, Goda T, Khodeir SA, et al. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol. 2017;11:915-9. doi: 10.1016/j.jacl.2017.04.115
4. Cherkashchenko NA, Livzan MA, Gaus OV, Krolevets TS. Non-alcoholic fatty liver disease and cholelithiasis: a random or regular combination? Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2019;3:40-4. (In Russ.) doi: 10.26442/26583739.2019.3.190489
5. Henson JB, Simon TG, Kaplan A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-36. doi: 10.1111/apt.15660
6. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol. 2017;5:384-93. doi: 10.14218/JCTH.2017.00013
7. Krolevets TS, Livzan MA. Clinical and laboratory markers for predicting liver fibrosis in individuals with nonalcoholic fatty liver disease. Exp Clin Gastroenterol. 2018;155(7):43-51. (In Russ.) eLIBRARY ID: 38200880
8. Livzan MA, Lapteva IV, Krolevets TS, Cherkaschenko NA. Leptin resistance in patients with nonalcoholic fatty liver disease associated with obesity and overweight. Med Sovet. 2015;13:58-63. (In Russ.) doi: 10.21518/2079-701X2015-13-58-63
9. Zhou D, Fan J-G. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(17):2019-28. doi: 10.3748/wjg.v25.i17.2019
10. Krasner YaA, Osipenko MF, Valuyskikh EYu, et al. Frequency and features of non-alcoholic fatty liver disease/steatohepatitis in patients with inflammatory bowel disease. J Siberian Med Sci. 2019;3:63-73. (In Russ.)

    file

    download